Table 2.

Patient transplant demographics

Patient	Follow-up	Cell source; HLA Match	Conditioning regimen	GvHD prophylaxis	Acute GvHD	Latest donor chimerism
1	6 years	URD PBSC 10/10	Alemtuzumab 1mg/kg Fludarabine 150mg/m2 Melphalan 140mg/m2	CSA MMF	-	CD15 55% CD19 55% CD3 86%
2	20 years	URD BM 10/10	Alemtuzumab 1mg/kg busulphan 16mg/kg Cyclophosphamide 200mg/kg	CSA	Grade 1 skin	WB 100%
3	11 years	URD BM 10/10	Alemtuzumab 1mg/kg Fludarabine 150mg/m2 Melphalan 140mg/kg	CSA MMF	-	WB 100%
4	3 years	MSD PBSC 10/10	Alemtuzumab 1mg/kg Treosulfan 42g/m2 Fludarabine150mg/m2	CSA MMF	Grade 1 skin	CD15 100% CD19 100% CD3 91%
5	3 years	URD PBSC 10/10	Alemtuzumab 1mg/kg Fludarabine 150mg/m2 Treosulphan 42g/m2	CSA MMF	Grade 1 skin	WB 100%
6	-	Mismatched URD PBSC 9/10 (DQ mismatch)	Alemtuzumab 60mg Fludarabine 150mg/m2 Melphalan 140mg/m2	CSA	-	Hyperacute rejection D+13
	2 years	URD BM 10/10	ATG Fludarabine 150mg/m2 Treosulphan 42g/m2 Thiotepa 10mg/kg	CSA MMF	-	WB 100%
7	20 months	URD PBSC 10/10	Alemtuzumab 1mg/kg Fludarabine 150mg/m2 Treosulphan 42g/m2	CSA MMF	-	WB 100%
8	15 months	MSD BM 10/10	Alemtuzumab 1mg/kg Fludarabine 150mg/m2 Treosulphan 42g/m2	CSA MMF	-	CD15 96% CD19 94% CD3 94%